Umoja Biopharma, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Umoja Biopharma, Inc.
Biotech entrepreneurs tend to be an optimistic group, and there were many pockets of hope for 2024. However, the consensus remains that depressed valuations and paucity of fresh funds will continue to pose a challenge for the sector, and companies will need to prioritize carefully and work even harder to demonstrate and create value.
Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.
Umoja’s technology is meant to enable development of CAR-Ts that could potentially overcome the challenges associated with autologous cell therapies, especially related to manufacturing.
Siegall is moving on after an unhappy exit from Seagen with a new role at another company with a novel targeted oncology platform.
- Gene Therapy, Cell Therapy
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.